Zoloft Sales Depressed By Adverse Publicity Surrounding Antidepressant Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer reports a 6% decline in Zoloft sales for third quarter, which the company attributes to publicity surrounding pediatric suicidality associated with antidepressants. FDA’s proposed relabeling likely means the end of TV ads for the brand.
You may also be interested in...
GSK Paxil DTC Pullback Decreases Downside From Black Box Requirement
GlaxoSmithKline does not foresee a significant impact from the antidepressant "black box" class warning requirement since it has already pulled back Paxil direct-to-consumer ads
Effexor Script Growth Will Double Antidepressant Market Rate, Wyeth Predicts
Effexor XR scripts grew 4% in the third quarter, compared to 2% growth for the category, Wyeth says. Sales of the antidepressant franchise jumped 46% in the U.S. in the third quarter. The company predicts “black box” class warning will not significantly impact Effexor, which is not advertised on TV.
GSK Paxil DTC Pullback Decreases Downside From Black Box Requirement
GlaxoSmithKline does not foresee a significant impact from the antidepressant "black box" class warning requirement since it has already pulled back Paxil direct-to-consumer ads